At Glooko, we believe being named a leader in CB Insights’ Diabetes Digital Therapeutics For Healthcare Payers — Execution & Market Strength Positioning (ESP) Vendor Matrix validates what our customers have been saying about our commitment to providing innovative digital health tools for chronic conditions like diabetes.
Glooko was among the select companies that CB Insights invited to participate in its December 2021 ESP evaluation, Diabetes Digital Therapeutics For Healthcare Payers — ESP Vendor Matrix. In this evaluation, Glooko was cited as a leader in digital therapeutics for diabetes.
“It’s an honor to see Glooko named a leader in diabetes digital therapeutics,” said Russ Johnannesson, CEO of Glooko. “Our team works hard to ensure our connected care solutions help people with diabetes and related chronic conditions and their healthcare provider better manage their disease and improve health outcomes.”
With diabetes being a leading driver of medical costs globally, it is one of the most prevalent chronic conditions in the U.S. That’s why we’re committed to delivering innovative platforms to healthcare providers, care management teams and patients in the U.S.—and around the world—to improve management of chronic conditions.
Through our population-level stratification tools, consumer-facing insulin dosing algorithms and industry-leading number of published clinical trials and patents, we’re improving care for people with chronic conditions like diabetes through collaboration and innovation.
MKT-0341 01
